X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
D | 2024-05-15 | PHGE | Orbimed Israel Biofund Gp Limited Partnership | 10% | S - Sale+OE | $0.38 | -24,344 | 13,773,653 | 0% | -$9,280 | |||||
2023-11-29 | PHGE | Oron Assaf | Chief Business Officer | S - Sale | $0.37 | -10,914 | 0 | -100% | -$4,072 | ||||||
2023-05-22 | PHGE | Oron Assaf | Chief Business Officer | P - Purchase | $0.27 | +3,192 | 10,914 | +41% | +$872 | ||||||
M | 2023-05-18 | PHGE | Oron Assaf | Chief Business Officer | P - Purchase | $0.28 | +7,722 | 7,722 | New | +$2,159 | |||||
D | 2023-02-27 | PHGE | Orbimed Israel Biofund Gp Limited Partnership | 10% | P - Purchase | $0.25 | +348,000 | 3,161,489 | +12% | +$85,260 | |||||
M | 2022-10-17 | PHGE | Ugwumba Chidozie | Exit Form 4 - former 10% owner | S - Sale | $0.35 | -74,955 | 2,997,025 | -2% | -$26,599 | |||||
M | 2022-09-16 | PHGE | Ugwumba Chidozie | Exit Form 4 - former 10% owner | S - Sale | $0.39 | -277,247 | 3,071,980 | -8% | -$107,247 | |||||
M | 2022-08-10 | PHGE | Ugwumba Chidozie | Exit Form 4 - former 10% owner | S - Sale | $0.64 | -288,619 | 3,349,227 | -8% | -$184,242 |
A | Amended filing |
D | Derivative transaction in filing (usually option exercise) |
E | Error detected in filing |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |